CBIH Cannabis Bioscience International Holdings, Inc.

Overview and Growth

Cannabis Bioscience International Holdings, Inc. generated $303.02K of revenue in fiscal 2025, with net loss of $548.82K and an operating cash outflow of $329.63K. Revenue of $303.02K sets the scale for evaluating how effectively sales translated into profit and cash during the year. Revenue was 21.8% above fiscal 2024 revenue of $248.84K, marking a year-over-year increase. On a per-share basis, diluted EPS was -$0.00, which connects the reported earnings outcome with the company’s diluted share count. A diluted share base of 10.72B links the aggregate earnings figure to diluted EPS and helps frame the per-share comparison. The diluted share count was 3.9% higher than fiscal 2024, when diluted shares averaged 10.32B, adding context to the EPS comparison. The company employed $31.88K of total assets, the balance-sheet base supporting its current operating and cash-flow results. The revenue-to-assets relationship was 9.51x, showing the sales generated relative to the resources carried on the balance sheet.

Profitability

Gross profit was $262.92K, representing the portion of revenue remaining after the reported cost of revenue and before operating expenses. Gross profit represented 86.8% of revenue, showing how much of the top line remained after direct costs. The reported operating result was an operating loss of $421.37K, reflecting costs that exceeded gross profit. An operating margin of -139.1% reflected costs exceeding revenue-level gross profit by 139.1% of sales. The company ended the period with a net loss of $548.82K, extending the operating result through all remaining items. Measured against revenue, the bottom-line deficit represented 181.1% after all recognized items. The net loss narrowed to $548.82K from $651.35K in fiscal 2024.

Liquidity and Capital Structure

The company held $31.88K of assets against $1.20M of liabilities and -$1.16M of equity, revealing how the asset base was financed. Equity was negative at -$1.16M, meaning liabilities exceeded the residual book value available to shareholders and weakening balance-sheet resilience. Current assets were $29.09K against $945.96K of current liabilities, framing the resources and obligations classified within the near-term balance-sheet horizon. Current assets covered only 0.03x of current liabilities, so current liabilities exceeded current assets at period end. The company held $12.95K in cash and equivalents, a narrower liquidity measure than total current assets. Cash and equivalents represented 1.4% of current liabilities, showing the portion of near-term obligations matched by reported cash alone. The company carried $264.09K of total debt at period end, which frames its leverage and debt-service burden. Relative to total assets, debt measured 828.4%, showing how much of the asset base was matched by borrowing. Measured against total assets, cash and equivalents represented 40.6%, a balance-sheet composition measure rather than a liquidity forecast. The asset base changed 44.2% from $57.16K in fiscal 2024, leaving current total assets lower year over year.

Cash Flow and Earnings Quality

Cash flow from operations was an outflow of $329.63K, showing that operations absorbed cash during the period. Compared with a $479.38K operating cash outflow in fiscal 2024, the current outflow improved to $329.63K.

Based on the annual report for the fiscal year ending May 31, 2025. Analysis generated Oct 21, 2026.